| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-10-08 | Opdivo® (nivolumab) | platinum-refractory patients with metastatic urothelial carcinoma | BMS (USA - NY) | Cancer - Oncology | |
| 2016-10-08 | Yervoy® (ipilimumab) | stage III melanoma patients at high risk of recurrence following complete surgical resection | 3 | BMS (USA - NY) | Cancer - Oncology - Rare diseases |
| 2016-10-08 | combination of dabrafenib and trametinib | metastatic melanoma with BRAF V600 mutations | 3 | Novartis (Switzerland) | Cancer - Oncology |
| 2016-10-07 | ASG-15ME | previously treated metastatic urothelial cancer | 1 | Seattle Genetics (USA - WA), a wholly owned subsidiary of Takeda Pharmaceutical (Japan) Agensys, an affiliate of Astellas (Japan) | Cancer - Oncology |
| 2016-10-07 | ABO-201 (AAV-CLN3) | Batten disease | preclinical | Abeona Therapeutics (USA - NY) | Rare diseases - Genetic diseases - Neurological diseases - Neurodegenerative diseases |
| 2016-10-06 | CHS-0214 (investigational etanercept biosimilar) | rheumatoid arthritis | 1 | Coherus Biosciences (USA - CA) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2016-10-06 | daratumumab in combination with lenalidomide and dexamethasone | multiple myeloma | 3 | Janssen Research & Development, a J&J company (USA - NJ) | Cancer - Oncology |
| 2016-10-06 | TOP1288 | ulcerative colitis | 2a | Topivert Pharma (UK) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2016-10-06 | Translarna™ (ataluren) | non-ambulatory nonsense mutation Duchenne muscular dystrophy patients (nmDMD) | preclinical | PTC Therapeutics (USA - NJ) | Rare diseases - Genetic diseases |
| 2016-10-06 | axicabtagene ciloleucel (KTE-C19 (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) and atezolizumab | refractory diffuse large B cell lymphoma (DLBCL) | 1-2a | Kite Pharma (USA - CA) Genentech, a member of Roche Group (USA - CA - Switzerland) | Cancer - Oncology |
| 2016-10-05 | preclinical | Transgene (France) | Cancer - Oncology | ||
| 2016-10-05 | Yeliva™ (ABC294640) | hepatocellular carcinoma | 2 | Redhill Biopharma (Israel) Apogee Biotechnology (USA - PA) | Cancer - Oncology |
| 2016-10-05 | ALN-TTRsc - revusiran | TTR-mediated amyloidosis (ATTR), TTR cardiac amyloidosis | 3 | Alnylam Therapeutics (USA - MA) | Rare diseases - Genetic diseases |
| 2016-10-05 | SCY-078 ((1,3)-ß-D-glucan synthesis inhibitor) | invasive candidiasis | 2 | Scynexis (USA - NJ) | Infectious diseases |
| 2016-10-04 | Precision Promise | pancreatic cancer | Pancreatic Cancer Action Network (USA) | Cancer - Oncology | |
| 2016-10-04 | Translarna™ (ataluren) | preclinical | PTC Therapeutics (USA - NJ) | Rare diseases - Genetic diseases | |
| 2016-10-03 | nonvalvular atrial fibrillation in elderly patients | registry study | Daiichi Sankyo (Japan) | Cardiovascular diseases | |
| 2016-10-03 | Cimzia® (certolizumab pegol) | moderate-to-severe chronic plaque psoriasis | 3 | UCB (Belgium) | Autoimmune diseases - Dermatological diseases |
| 2016-10-01 | Dupixent® (dupilumab) | moderate-to-severe atopic dermatitis | 3 | Sanofi (France) Regeneron Pharmaceuticals (USA - NY) | Dermatological diseases - Inflammatory diseases |
| 2016-10-01 | tildrakizumab | moderate-to-severe plaque psoriasis | 3 | Merck&Co (USA - NJ) Sun Pharmaceuticals (India) | Autoimmune diseases - Dermatological diseases - Inflammatory diseases |
